Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion–Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study

Abstract PURPOSE Patients with lower-risk (LR) myelodysplastic syndromes (MDS) who are RBC transfusion dependent and have experienced relapse after or are refractory to erythropoiesis-stimulating agent (ESA) have limited treatment options. High telomerase activity and human telomerase reverse-transcription expression in clonal hematopoietic cells have been reported in patients with MDS. Imetelstat, a first-in-class competitive inhibitor of…

Opportunità professionale per medici ricercatori presso humanitas research hospital Milano

Carissimi Amici e Colleghi, Vi scrivo con l’intento di diffondere all’interno della nostra rete nazionale MDS una possibile opportunità per giovani ematologi. A Milano in Humanitas partirà nei prossimi mesi un progetto Europeo focalizzato sulla ricerca traslazionale nelle MDS, dal titolo “An integrated European platform to conduct translational studies in Myelodysplastic Syndromes based on the…